The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retrospective study of nivolumab monotherapy for advanced esophageal squamous cell carcinoma.
 
Hayato Mikuni
No Relationships to Disclose
 
Shun Yamamoto
No Relationships to Disclose
 
Kotoe Oshima
No Relationships to Disclose
 
Hidekazu Hirano
No Relationships to Disclose
 
Natsuko Okita
No Relationships to Disclose
 
Hirokazu Shoji
Research Funding - Amgen; Astellas Pharma; MSD; Ono Pharmaceutical
 
Yoshitaka Honma
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai/Roche; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Teijin Pharma
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Loxo (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Rakuten Medical (Inst); Taiho Pharmaceutical (Inst)
 
Satoru Iwasa
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - LSK BioPharma; Sumitomo Group; Takeda
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)